Advitech builds R&D behind Dermylex

By staff reporter

- Last updated on GMT

Related tags: Finance, North america

In the latest plug for its psoriasis ingredient and product
Dermylex, Advitech has closed a private placement for a total of

Of the sum, $448,000 comes from issuing convertible debentures and another $436,128 comes of from the issuance units. The Quebec-based company has been aggressively pushing R&D as well as promotion and distribution agreements behind the innovative product. "This financing will give us an additional leeway and will allow us to reach our 2007 commercial goals and others objectives linked to our R&D program,"​ said Renaud Beauchesne, Advitech president and CEO. "In addition, we are currently evaluating additional opportunities to finance our activities in order to strengthen our financial capacity." ​An estimated 6 million adults in North America suffer from the skin disease psoriasis, potentially opening-up a large market for a natural oral alternative, such as Dermylex, to target the condition. Dermylex is a patented blend of naturally derived bioactive peptides that comes in the form of a tablet to be taken orally. While the company originally designed an ingredient, it has increasingly shifted promotion towards its own finished psoriasis product. After numerous years of development, Advitech has begun to roll out Dermylex via distribution agreements with companies such as Canadian Jamieson Laboratories. As well, the company has secured numerous athletic spokespeople to represent the branded product.

Related topics: Proteins, peptides, amino acids

Related news

Show more

Related products

show more

INNOBIO® Vegan EAAs Enhanced with Vegan CLA

INNOBIO® Vegan EAAs Enhanced with Vegan CLA

INNOBIO Corporation Limited | 19-Aug-2019 | Technical / White Paper

It is known to all that EAAs can improve muscle growth and exercise performance, as well as increase lean body mass and prevent muscle loss. INNOBIO® EAAs...

Fermented Soy for Natural Digestive Support

Fermented Soy for Natural Digestive Support

Lallemand Bio-Ingredients | 22-Apr-2019 | Technical / White Paper

Lallemand is running a new clinical trial for Gastro-AD® in spring 2019. Gastro-AD® is a clinically studied food supplement based on non-GMO soy fermented...

Related suppliers

Follow us

Featured Events

View more


View more